MyFinsight
Home
Blog
About
Income Statement
|
Cash Flow
|
Balance Sheet
|
Ratios
Income Overview
Net Income
-$7,644K
EPS
-$0.27
Unit: Thousand (K) dollars
Subscribe for Financial Insights
Page 1
Quarterly
123
Page 1
Income Statement
2025-09-30
2025-06-30
2025-03-31
2024-12-31
Total revenue
-
-
-
2,996*
Research and development
2,239
4,739
4,156
7,112*
General and administrative
5,314
2,550
3,432
3,306*
Total cost and expenses
7,553
7,289
7,588
10,418*
Operating loss
-7,553
-7,289
-7,588
-7,422*
Interest income
537
607
713
939*
Interest expense
-
-
129
129*
Gain on extinguishment of borrowings
-
-
5,203
-
Foreign currency exchange (loss) gain, net
-166
-1,885
-1,453
492*
Total other income (expense), net
371
-1,278
4,334
1,302*
Net loss before taxes
-7,182
-8,567
-3,254
-6,120*
Income tax expense
6
72
225
158*
Net loss
-7,188
-8,639
-3,479
-6,278*
Foreign currency translation adjustment
-456
2,349
978
-439*
Comprehensive loss
-7,644
-6,290
-2,501
-6,718
Basic EPS
-0.27
-0.32
-0.13
-0.25
Diluted EPS
-0.27
-0.32
-0.13
-0.25
Basic Average Shares
26,899,122
26,899,122
26,892,575
26,834,422
Diluted Average Shares
26,899,122
26,899,122
26,892,575
26,834,422
Page 1
Unit: Thousand (K) dollars (except for numbers of shares and EPS). Numbers labeled with * are estimated quarterly values.
Page 1
Buy us a coffee
Time Plot
Show the time plot by selecting a row from the table.
Income Statement
Comprehensive loss
-$7,644K
Net loss
-$7,188K
Foreign currency
translation adjustment
-$456K
Interest income
$537K
Net loss before
taxes
-$7,182K
Income tax expense
$6K
Total other income
(expense), net
$371K
Foreign currency
exchange (loss) gain, net
-$166K
Operating loss
-$7,553K
Total cost and
expenses
$7,553K
General and
administrative
$5,314K
Research and development
$2,239K
Buy us a coffee
LAVA Therapeutics NV (LVTX)
LAVA Therapeutics NV (LVTX)